August 31, 2015 – Adding sitagliptin to usual diabetes care does not increase the risk of heart failure, according to results from the TECOS study presented at the European Society of Cardiology Congress.
The latest results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) were presented in London today at the European Society of Cardiology’s Annual Congress.
The results were presented by Frans Van de Werf, MD, PhD, professor at the Department of Cardiovascular Diseases, University Hospital Gasthuisberg, and director of the Leuven Coordinating Centre in Leuven, Belgium.
DCRI Executive Director Eric Peterson, MD, MPH, serves as co-chair of the TECOS Executive Committee.
In a placebo-controlled, multinational cardiovascular safety study of the diabetes drug sitagliptin, researchers found that the drug demonstrated no increase in hospitalization for heart failure, including in patients with heart failure. Additional findings, including analysis of the composite endpoints of hospitalization for heart failure or cardiovascular death, and hospitalization for heart failure or all-cause mortality, were presented at the congress and revealed no differences between the treatment groups.
“This study provides reassurance to patients and prescribers about the cardiovascular safety of this drug,” Van de Werf said. “This study is therefore very important not only for endocrinologists but also for cardiologists who see many patients with diabetes and coronary heart disease treated with sitagliptin.”
Paul Armstrong, MD, Distinguished University Professor at the University of Alberta and Founding Director of the Canadian VIGOUR Centre, commented, “Heart failure in diabetes is a serious complication that extracts big penalties down the line in these patients. Because heart failure has been associated with some treatments for diabetes, it’s comforting to know that sitagliptin can be used safely without that concern.”
The analysis of TECOS involved 14,671 patients with type 2 diabetes and established cardiovascular disease, who were randomized, double-blind, to sitagliptin (7,332) or placebo (7,339) added to usual care, with open label addition of other antihyperglycemic medications in both groups to achieve similar glycemic targets, in accordance with regional guidelines.